Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:7:63-9.
doi: 10.2147/OPTH.S39503. Epub 2013 Jan 9.

Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure

Jacky Wy Lee  1 , Jimmy Sm Lai, Doris Wf Yick, Can Yf Yuen
Affiliations

Argon laser peripheral iridoplasty versus systemic intraocular pressure-lowering medications as immediate management for acute phacomorphic angle closure

Jacky Wy Lee et al. Clin Ophthalmol. 2013.

Abstract

Background: The purpose of this study was to compare the efficacy and safety of argon laser peripheral iridoplasty (ALPI) and systemic intraocular pressure (IOP)-lowering medications in the immediate management of acute phacomorphic angle closure.

Methods: Consecutive cases of acute phacomorphic angle closure were randomized to receive ALPI and an intravenous or oral carbonic anhydrase inhibitor as initial treatment. Intravenous mannitol was administered for presenting IOP > 60 mmHg or IOP > 40 mmHg 2 hours posttreatment in both arms.

Results: Of 10 consecutive cases, six received medical therapy and four received ALPI. Fifty percent in the medical group and none in the ALPI group required intravenous mannitol. The ALPI group took less time to achieve IOP < 25 mmHg (18.8 ± 7.5 minutes versus 115.0 ± 97.0 minutes, P = 0.001, F test); had a greater IOP reduction within 30 minutes (69.8% ± 7.7% versus 40.9 ± 23.9%, P = 0.03, t-test); and had a consistently smaller post-attack cup to disc ratio (0.50 ± 0.02 versus 0.60 ± 0.20, P = 0.002, F test).

Conclusion: ALPI offers greater safety, consistency, and efficacy than systemic IOP-lowering medications as initial treatment for phacomorphic angle closure.

Keywords: argon laser peripheral iridoplasty; glaucoma; intraocular pressure; medical; phacomorphic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percentage of IOP reduction following treatment. Abbreviations: ALPI, argon laser peripheral iridoplasty; IOP, intraocular pressure.
Figure 2
Figure 2
Time taken to lower IOP to <25 mmHg. Abbreviations: ALPI, argon laser peripheral iridoplasty; IOP, intraocular pressure.
Figure 3
Figure 3
Amount of IOP reduction within the first 30 minutes of treatment. Abbreviations: ALPI, argon laser peripheral iridoplasty; IOP, intraocular pressure.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Leibmann JM, Ritch R. Glaucoma associated with lens intumescence and dislocation. In: Ritch R, Shields MB, Krupin T, editors. The Glaucomas. 2nd ed. St Louis, MO: Mosby; 1996.
    1. David R, Tessler Z, Yassur Y. Long term outcome of primary acute angle closure glaucoma. Br J Ophthalmol. 1993;17:33–36. - PMC - PubMed
    1. Kanellopoulos AJ, Perry HD, Donnenfeld ED. Comparison of topical timolol gel to oral acetazolamide in the prophylaxis of viscoelastic-induced ocular hypertension after penetrating keratoplasty. Cornea. 1997;16:12–15. - PubMed
    1. Hart WM, Becker B. The onset and evolution of glaucomatous visual field defect. Ophthalmology. 1982;89:991–998. - PubMed
    1. Berson FG, Ebstein DL. Carbonic anhydrase inhibitors: management of side effects. Perspect Ophthalmol. 1980;4:91–96.

LinkOut - more resources